Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer ; volume:18 ; number:5 ; day:16 ; month:9 ; year:2023 ; pages:801 ; date:9.2023
Targeted oncology ; 18, Heft 5 (16.9.2023), 801, 9.2023
- Urheber
-
Lee, Arnold
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-023-01003-2
- URN
-
urn:nbn:de:101:1-2023121213132843420715
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Arnold
- SpringerLink (Online service)
Ähnliche Objekte (12)
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review